👏👏 excellent and clarifier “openmind” presentations of both Andrea Necchi and Tom Powles regard the status of MIUC management! My opinion biomarker selected bladder sparing preservation program is the future !! #precisionmedicine #GUARDSymposium2024 OncoAlert Sabine D. Brookman-May

Out now! "Targeted Investigational Treatment Analysis of Novel Anti‐androgen (TITAN) study: ultralow prostate‐specific antigen decline with apalutamide plus androgen‐deprivation therapy" BJU International Simon C Neeraj Agarwal, MD, FASCO Sabine D. Brookman-May Anders Bjartell bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bj…

It would be great to develop a bladder sparing approach #BladderCancer #MIBC ✅Biomarker selected ✅Biomarker guided during/after treatment ✅with no risk for patients of missing the right time point of #RadicalCystectomy if still needed ✅+maintained QoL OncoDaily Daniel Castellano

Tyler Seibert MD PhD Shiv Smith 💙 Corey Speers Lauren Henke, MD, MSCI Aadel Chaudhuri, MD PhD Vedang Murthy Andreas Røder Henning Willers, MD Caroline Moore Renu Eapen Shankar Siva Simon C Mariam Aboian Matt Hobbs Adam Sharp Simon Lord 🇺🇦 💙alison birtle Anthony Chalmers 💙 Alex Wyatt Tony Collier BEM Josh Lang Alan Dal Pra, MD Dr. Brandon Mahal Kosj Yamoah MD, PhD Christine Feng American Association of Physicists in Medicine I was so inactive on X recently that I even missed to post my ride 2 weeks ago from #Bavaria to Lago di Garda #Italy 🚴‍♂️🚴‍♂️🚴‍♂️🚴‍♂️🚴‍♂️ Great #Roadbike tour in a group of 5 great female cyclists: 330 km in one step, startet 3:30 am and arrived at 6:30 right in time for dinner 💪

🎯😎🎯😎… the ESMO - Eur. Oncology football 2024 tournament is coming!! 📣Stay tuned!! #ESMO24 Toni Choueiri, MD FabriceAndre ASCO ⚽️🥅🏃‍♂️🏃‍♂️👟🚴‍♀️🚴‍♀️ Sport is already an important key point on the ESMO - Eur. Oncology and ASCO agenda!!🔥 - OncoAlert running Gil Morgan, MD - Toni Choueiri, MD Daniel Castellano FabriceAndre

▶️Molecular #biomarkers for #NMIBC subtyping to better predict progression + provide molecular targets for precision medicine ▶️Exploration of mechanisms underlying NMIBC #progression after BCG treatment is needed for potential bladder-sparing approaches 👉nature.com/articles/s4158…

It was great to speak again with Charles Spence, my favorite perpetual headhunter in his #podcast 🎧 “A Dose of Reality” about leadership and equality in Clinical #Development and #RnD and several other topics 👉lnkd.in/dVAh3BFt

Need to give Deutsche Lufthansa another positive feedback for my last DE-US flight- it was a great one! Contrary to americanair: planned to fly SF-Philly 12 pm with my kids - after 12 hrs now in Phoenix - no way to Philly or east coast for another day Solution-orientated mindset?

Words of Wisdom Re: Achieving Benchmarks for National Quality Indicators Reduces Recurrence and Progression #NMIBC #BladderCancer ✅ Shining example of the impact of consistently applied evidence-based interventions 👉sciencedirect.com/science/articl… Ashish M. Kamat, MD, MBBS European Urology Prof Param Mariappan 🇬🇧 🇲🇾

⚡️Integrative Drug Screening and Multiomic Characterization of Patient-derived Bladder Cancer Organoids Reveal Novel Molecular Correlates of Gemcitabine Response #BladderCancer European Urology europeanurology.com/article/S0302-…

Would have loved to join this season Sarah P. Psutka MD MS Shilpa Gupta but not joining IBCG retreat this year 👉 still a way to go to develop the best endpoints in IR #NMIBC that make clinical and regulatory sense and for from a #patient perspective Ashish M. Kamat, MD, MBBS Roger Li

Leaving the #US after 2 years ✈️ and relocating back to Germany #Bavaria 🇩🇪🥨🍻🏔️ It was a great time in 🇺🇸and I will truly miss it - and at the same time very happy to be in #Europe again Especially happy also that my luggage arrived including my Bianchi #Roadbike 🚴‍♂️

Unpacked my #roadbike now and it looks like my happiness was too early 😬 TSA checked my bike luggage and it looks like they removed the front quick release (it is not even anywhere in the luggage anymore) and didn’t put it back in and now the front carbon fork is damaged 😡

Bladder-sparing therapy for BCG-unresponsive NMIBC should be personalized. Options include: Gemcitabine/Docetaxel, Nadofaragene Firadenovec, and Pembrolizumab, with consideration of efficacy and toxicity. ⭕️Radical cystectomy remains the gold standard. #BladderCancer #Oncology

Sharing our Words of Wisdom about factors impacting #treatment decision making +#DecisionRegret in patients with #ProstateCancer ➡️Patients wish to actively participate and we should regard this as a mandate Maarten Albersen #MatthiasMay European Urology 👉sciencedirect.com/science/articl…

Managing variant histology in high-risk non-muscle invasive #BladderCancer. Cookson, Michael University of Oklahoma Urology & Paolo Gontero MolinetteUrology discuss with Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center as part of the IBCG #BladderCancerForum > bit.ly/3xyeyRr

Excellent exchange and discussion Sam S. Chang MD, MBA Ashish M. Kamat, MD, MBBS Matt Galsky #BladderCancer ✅ need for #control arms in clinical trials reflecting SOC #NMIBC ✅ need for accurate risk categorization of patients ✅ role of #Biomarkers - #ctDNA 👉 bit.ly/4bcYVxh UroToday.com

Listen in to get prepared for #ESMO2024 👉 Uromigos⁩ episode ⁦with ⁦silke gillessen⁩ ⁦Brian Rini, MD⁩ ⁦Tom Powles⁩ podcasts.apple.com/de/podcast/the…